Jackie Collins

Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.

Patients with advanced or metastatic endometrial cancer experienced a significant non-progression rate following treatment with olaparib, metronomic cyclophosphamide, and metformin.

The ongoing KEYNOTE-B21 trial aims to determine if pembrolizumab plus adjuvant chemotherapy with or without radiotherapy will improve disease-free survival and overall survival in patients with newly diagnosed endometrial cancer.

Better health-related quality of life outcomes were associated with nivolumab and cabozantinib for advanced renal cell carcinoma vs sunitinib.

Data from the phase 3 DESTINY-Breast03 trial show trastuzumab deruxtecan bests trastuzumab emtansine in patients with previously treated HER2-positive metastatic breast cancer.

Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.